KR880010759A - 방출 조절성 제제 - Google Patents

방출 조절성 제제 Download PDF

Info

Publication number
KR880010759A
KR880010759A KR1019880003222A KR880003222A KR880010759A KR 880010759 A KR880010759 A KR 880010759A KR 1019880003222 A KR1019880003222 A KR 1019880003222A KR 880003222 A KR880003222 A KR 880003222A KR 880010759 A KR880010759 A KR 880010759A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
pharmaceutical
controlled release
coating
zidovudine
Prior art date
Application number
KR1019880003222A
Other languages
English (en)
Other versions
KR960013434B1 (ko
Inventor
필립 죤스 해리
져슨 맥키 로버트
죤 데스몬드 갬렌 미카엘
Original Assignee
마이클 피터 잭슨
더 웰컴 화운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이클 피터 잭슨, 더 웰컴 화운데이션 리미티드 filed Critical 마이클 피터 잭슨
Publication of KR880010759A publication Critical patent/KR880010759A/ko
Application granted granted Critical
Publication of KR960013434B1 publication Critical patent/KR960013434B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

방출 저절성 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 지도부딘을 함유하는 낱개의 단위 각에 (a) 아크릴 및 메타크릴산의 알킬 에스테르 화합물로부터 선택된 최소한 일종의 단량체로 구성된 비이온성 중합체와 (b) 에틸 셀룰로오즈로 구성된 혼합물을 함유하는 방출 조절성 피복제가 제공되며, 이 피복제 내에 성분(a) 및 (b)가 1:3 내지 3:1의 중량비로 존재하는 구강 투여용 약학적 제제.
  2. 제 1 항에 있어서 방출 조절성 피복제 중의 성분(a)는 아크릴 및/또는 메타크릴산의 C1-4알킬 에스테르 화합물 일종 또는 그 이상으로 구성된 단일 중합체를 함유하는 것을 특징으로 하는 약학적 제제.
  3. 제 1 항 또는 제 2 항에 있어서, 상기 방출 조절성 피복제가 다공 형성제를 포함하는 것을 특징으로 하는 약학적 제제.
  4. 제항에 있어서 다공 형성제가 만니톨인 것을 특징으로 하는 약학적 제제.
  5. 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, 성분(a) 및 (b)가 약 1:1의 중량비로 피복제 내에 존재하는 것을 특징으로 하는 약학적 제제.
  6. 제 1 항 내지 제 5 항 중 어느 한 항에 있어서 상기 펠리트가 0.5 내지 2mm의 직경을 갖는 구형입자인 약학적 제제.
  7. 75-99%의 지도부딘을 활성성분으로 포함하며 또한 일종 또는 2이상의 부형제를 함께 포함하는 균일 혼합물로 구성되어 있고 0.5 내지 2mm의 직경을 갖는 구형입자의 형태로 구강 투여되는 약학적 제제.
  8. 제 7 항에 있어서 상기 구형입자는 최소한 80%중량/중량의 지도부딘을 함유하는 약학적 제제.
  9. 제 7 항 또는 제 8 항에 있어서 약학적 부형제가 미립결정성 셀룰로오즈인 약학적 제제.
  10. 제 7 항 내지 제 9 항 중 어느 한 항에 있어서 제 1 항 내지 제 5 항에서 정의된 방출조절성 피복제가 제공된 약학적 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880003222A 1987-03-27 1988-03-25 서방성 제제 KR960013434B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8707421 1987-03-27
GB878707421A GB8707421D0 (en) 1987-03-27 1987-03-27 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
KR880010759A true KR880010759A (ko) 1988-10-24
KR960013434B1 KR960013434B1 (ko) 1996-10-05

Family

ID=10614823

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003222A KR960013434B1 (ko) 1987-03-27 1988-03-25 서방성 제제

Country Status (17)

Country Link
US (1) US4917900A (ko)
EP (1) EP0284407B1 (ko)
JP (1) JP2719344B2 (ko)
KR (1) KR960013434B1 (ko)
AT (1) ATE63818T1 (ko)
AU (1) AU607474B2 (ko)
CA (1) CA1308026C (ko)
DE (1) DE3862974D1 (ko)
DK (1) DK175348B1 (ko)
ES (1) ES2033426T3 (ko)
GB (1) GB8707421D0 (ko)
GR (1) GR3002030T3 (ko)
IE (1) IE60605B1 (ko)
IL (1) IL85870A (ko)
NZ (1) NZ224026A (ko)
PT (1) PT87081B (ko)
ZA (1) ZA882168B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US4938966A (en) * 1988-11-30 1990-07-03 Riker Laboratories, Inc. Controlled release flecainide acetate formulation
GB8912420D0 (en) 1989-05-31 1989-07-19 Schram Cornelius J Ultrasonic systems
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU2181592A (en) * 1991-06-21 1993-01-25 Acic (Canada) Inc. Novel anti-viral compounds and processes for production of anti-viral compounds
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
ATE186544T1 (de) * 1992-08-04 1999-11-15 James M Dunn Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
HUP0302631A2 (hu) * 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20050256234A1 (en) * 2002-06-24 2005-11-17 Asahi Denka Co., Ltd Flame retardant composition and flame retardant resin composition containing the composition
WO2004043433A2 (en) * 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
UA82564C2 (uk) * 2003-10-01 2008-04-25 Люпин Лимитед Антиретровірусна фармацевтична композиція керованого вивільнення та спосіб її виготовлення
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
CN106333957A (zh) * 2016-08-19 2017-01-18 丁静 齐多夫定用于制备自身免疫性神经炎治疗药物的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE145365C (ko) *
BE785702A (fr) * 1971-07-14 1972-10-16 Roehm Gmbh Produits de revetement de formes medicamenteuses et leur utilisation
BE787973A (fr) * 1971-09-04 1973-02-26 Beecham Group Ltd Comprimes pharmaceutiques a effet retard
ES438635A1 (es) * 1974-06-24 1977-02-16 Shinetsu Chemical Co Procedimiento para el revestimiento de moldes solidos de do-sificacion.
EP0052076B1 (de) * 1980-11-12 1985-05-29 Ciba-Geigy Ag Schnellzerfallende Arzneimittel-Presslinge
EP0052075A1 (de) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Körnige Arzneimittel-Retardform
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
IT1168014B (it) * 1981-08-05 1987-05-20 Erba Farmitalia Forme farmaceutiche a cessione protratta
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
JPS59227817A (ja) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd 持続性経口用ブレデニン製剤
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
EP0196185B1 (en) * 1985-03-16 1989-07-12 The Wellcome Foundation Limited Antiviral nucleosides
GB8506869D0 (en) * 1985-03-16 1985-04-17 Wellcome Found Antiviral compound
CA1285935C (en) * 1985-03-16 1991-07-09 Janet Lister Rideout Therapeutic nucleosides
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB2209669B (en) * 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same

Also Published As

Publication number Publication date
DK164388D0 (da) 1988-03-25
DK175348B1 (da) 2004-09-06
AU607474B2 (en) 1991-03-07
DK164388A (da) 1988-09-28
IE60605B1 (en) 1994-07-27
CA1308026C (en) 1992-09-29
US4917900A (en) 1990-04-17
NZ224026A (en) 1991-03-26
EP0284407A2 (en) 1988-09-28
DE3862974D1 (de) 1991-07-04
JP2719344B2 (ja) 1998-02-25
ZA882168B (en) 1989-11-29
IE880899L (en) 1988-09-27
ATE63818T1 (de) 1991-06-15
GR3002030T3 (en) 1992-12-30
AU1375688A (en) 1988-09-29
EP0284407A3 (en) 1988-12-14
KR960013434B1 (ko) 1996-10-05
JPS63255230A (ja) 1988-10-21
PT87081A (pt) 1988-04-01
ES2033426T3 (es) 1993-03-16
GB8707421D0 (en) 1987-04-29
IL85870A (en) 1992-02-16
EP0284407B1 (en) 1991-05-29
PT87081B (pt) 1992-07-31

Similar Documents

Publication Publication Date Title
KR880010759A (ko) 방출 조절성 제제
EP0086093B1 (en) Long-lasting three layered pharmaceutical film preparations
KR890700344A (ko) 약학 제제
KR880010758A (ko) 서방성 제제
KR910011242A (ko) 서방성 약학제제 및 그의 제조방법
KR920702618A (ko) 약제학적 제형
KR920021140A (ko) 약학 조성물
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
KR880004804A (ko) 분무건조 아세트 아미노펜
DK0430287T3 (da) Doseringsenheder til vedvarende afgivelse af et lægemiddel
KR870000069A (ko) 안정한 고체 제형의 제조 방법
KR850001693A (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
KR880000090A (ko) 서방형 이부프로펜 제제의 제조방법
ES462418A1 (es) Un procedimiento para la preparacion de composiciones biolo-gicamente activas.
KR870007121A (ko) 지속성 서방출형 약제학적 조성물
DE3856258D1 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
ATE180969T1 (de) Pharmazeutische zusammensetzungen enthaltend urodeoxycholicsäure
EP0297866A3 (en) Therapeutic agents
PH26014A (en) Water dispersible gemfibrozil compositions
ES2032125T3 (es) Forma galenica para la liberizacion prolongada del diltiazem.
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
TH5433EX (th) สูตรผสมในทางเภสัชกรรมของแอไครแวสทีน

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100930

Year of fee payment: 15

EXPY Expiration of term